Abstract
In 2001 the laboratory of Catherine Verfaillie at the University of Minnesota described the multipotent adult progenitor cell (MAPC) as a novel progenitor cell present in adult marrow that is biologically and antigenically distinct from the mesenchymal stem cell (MSC). MAPCs represent a more primitive progenitor cell population than MSCs and demonstrate remarkable differentiation capability along the epithelial, endothelial, neuronal, myogenic, hematopoeitic, osteogenic, hepatic, chondrogenic, and adipogenic lineages. MAPCs thus embody a unique class of adult stem cells that emulate the broad biological plasticity characteristic of embryonic stem (ES) cells, while maintaining the characteristics that make adult stem cells more amenable to therapeutic application. MAPCs have been reported to be capable of prolonged culture without loss of differentiation potential, and of showing efficient, long-term engraftment and differentiation along multiple developmental lineages in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice without evidence of teratoma formation. Based on these findings, there is great interest in evaluating the therapeutic value of MAPCs for a variety of human genetic and degenerative ailments, including cardiovascular disease.
This chapter will focus on reviewing MAPCs and other adult stem cells displaying broad, pluripotent differentiation potential as cellular therapeutics with application for myocardial repair in heart disease. For clarity, the MAPC acronym will be used specifically to represent the cell population originally described by or acquired from the laboratory of Catherine Verfaillie and collaborators. Pluripotent adult stem cell cultures reported by other researchers will be referred to in accordance with designations used in the original publications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zhang J, Narula J. Molecular biology of myocardial recovery. Surg Clin North Am 2004;84(1):223–242.
Lee MS, Lill M, Makkar RR. Stem cell transplantation in myocardial infarction. Rev Cardiovasc Med 2004;5(2):82–98.
Fedak PW, Weisel RD, Verma S, Mickle DA, Li RK. Restoration and regeneration of failing myocardium with cell transplantation and tissue engineering. Semin Thorac Cardiovasc Surg 2003;15(3):277–286.
Raff M. Adult stem cell plasticity: fact or artifact? Annu Rev Cell Dev Biol 2003;19:1–22.
Verfaillie CM. Adult stem cells: assessing the case for pluripotency. Trends Cell Biol 2002;12(11):502–508.
Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality. Hematology (Am Soc Hematol Educ Program) 2002:369–391.
Verfaillie CM, Schwartz R, Reyes M, Jiang Y. Unexpected potential of adult stem cells. Ann N YAcad Sci 2003;996:231–234.
Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell 2004;116(5):639–648.
Cai J, Rao MS. Stem cell and precursor cell therapy. Neuromolecular Med 2002;2(3):233–249.
Verfaillie CM. Hematopoietic stem cells for transplantation. Nat Immunol 2002;3(4):314–317.
Palaganas J, Civin CI. Two steps forward: keeping the momentum in stem cell research. Stem Cells 2004;22(3):240–241.
Ivanovic Z, Hermitte F, de la Grange PB, et al. Simultaneous maintenance of human cord blood SCID-repopulating cells and expansion of committed progenitors at low O2 concentration (3%). Stem Cells 2004;22(5):716–724.
Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428(6983):664–668.
Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428(6983):668–673.
Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284(5411):143–147.
Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95(1):9–20.
Shake JG, Gruber PJ, Baumgartner WA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73(6):1919–1926.
Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2004;109(25):3154–3157.
Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002;30(8):896–904.
Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann NY Acad Sci 2001;938:231–235.
Anjos-Afonzo F, Bonnet D. SSEA-1 defines the most primitive cell-type in adult murine mesenchymal stem cell (MUMSCS) compartment with multipotential activity in vitro and in vivo including hematopoietic reconstitution capacity. In: Third Annual Meeting of the International Society for Stem Cell Research, 2005, San Francisco, CA, 2005,35.
Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418(6893):41–49.
Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001;29(5):543–556.
Yasuhara T, Matsukawa N, Yu G, et al. Transplantation of cryopreserved human bone marrow-derived multipotent adult progenitor cells for neonatal hypoxic-ischemic injury: targeting the hippocampus. Rev Neurosci 2006;17(1,2):215–225.
Pittenger MF, Mosca JD, McIntosh KR. Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol 2000;251:3–11.
Jiang Y, Breyer A, Lien L, Blackstad M, Verfaillie C. Culture of multipotent adult progenitor cells (MAPCs). ASH Annual Meeting Abstracts 2004;104(11):23–29.
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99(10):3838–3843.
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75(3):389–397.
Barry FP, Murphy JM, English K, Mahon BP. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 2005;14(3):252–265.
Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439–1441.
Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005;115(2):326–338.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Hof, W.v. et al. (2007). Multipotent Adult Progenitor Cells. In: Penn, M.S. (eds) Stem Cells And Myocardial Regeneration. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-272-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-59745-272-4_4
Publisher Name: Humana Press
Print ISBN: 978-1-58829-664-1
Online ISBN: 978-1-59745-272-4
eBook Packages: MedicineMedicine (R0)